Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Comment by KayakerBCon Aug 08, 2022 11:42am
147 Views
Post# 34878843

RE:RE:RE:RE:S&P Biotech ETF enters bull market up 29% in 13 trading days

RE:RE:RE:RE:S&P Biotech ETF enters bull market up 29% in 13 trading daysMoney is flooding the sector.

A common fallacy. Other than IPOs and share offerings, money doesn't "flood" or flow into the stock market or any part of it.  That's part of the fallacy of "cash on the sidelines".  Money doesn't flow into or out of the stock market -- it flows through it.  Any stock that is purchased is sold by someone else, at the same price.  Stocks move up because buyers are more enthusiastic than sellers -- again, not because of an increased "flow" of money into the market.
<< Previous
Bullboard Posts
Next >>